Home > Dermatology > PFGC 2021 > Best of the Posters > High treatment success with ixekizumab in patients with psoriasis and diabetes

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By
Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
PFGC 2021
Trial
Phase 3, UNCOVER
A marked proportion of participants from 3 phase 3 psoriasis trials with comorbid diabetes experienced a benefit in the Psoriasis Area and Severity Index (PASI) with ixekizumab. The post-hoc analysis of these trials also detected no deterioration of blood pressure, body mass index (BMI), and lipid profile. The anti-IL-17A antibody ixekizumab has been assessed for treatment of moderate-to-severe psoriasis within the UNCOVER trials (NCT01474512, NCT01597245, NCT01646177) [1,2]. The results revealed long-term maintained efficacy and consistent safety up to 5 years of treatment. A new post-hoc analysis by Dr Alexander Egeberg (Copenhagen University Hospital Gentofte, Denmark) and co...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on